Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer
NCT05181826
This study is recruiting at 6 US sites in 3 states, according to its ClinicalTrials.gov record last updated .
Summary
To acquire blood samples from subjects for various purposes, including: i) determining the sensitivity and specificity of select DNA methylation markers for the detection of various types of cancer, ii) identifying benign conditions that may induce false positive or false negative results, and iii) defining the effects of potential interfering substances, such as chemotherapy drugs.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Cancer
- Liver Cirrhosis
- Chronic Hepatitis
- Hepatitis B
- Hepatitis C
- Diabetes
- COPD
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Helio Genomics
- Last updated on ClinicalTrials.gov
- July 10, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Minnesota · 3
- Allina Health, Virginia Piper Cancer Institute · Coon Rapids, MN
- Virginia Piper Cancer Institute Mercy Hospital-Unity Campus · Fridley, MN
- VPCI Oncology Research · Minneapolis, MN
Tennessee · 1
- Methodist LeBonheur Healthcare · Memphis, TN
Texas · 2
- Liver Center of Texas · Dallas, TX
- Methodist Hospital · Richardson, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.